Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Methylmalonic Acidemia (MMA) Market from 2024 to 2025?

The methylmalonic acidemia (MMA) market has seen substantial growth in the past few years. The market is projected to increase from $9.39 billion in 2024 to $9.97 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.2%. This growth during the historic period has been fueled by various factors such as the rising occurrence of metabolic disorders and vitamin deficiencies, higher healthcare spending, an uptick in health awareness, a surge in cases of genetic disorders, and the escalating demand in different end-user sectors.

What Is the Projected Market Size of the Methylmalonic Acidemia (MMA) Market?

In the coming years, the methylmalonic acidemia (MMA) market is anticipated to experience robust growth. By 2029, the market is projected to increase to a value of $12.50 billion, with a compound annual growth rate (CAGR) of 5.8%. The growth in the estimated period could be due to factors such as heightened newborn screening initiatives, improved awareness among health care professionals, progress in gene therapy, increased funding for rare disease research, and enhanced access to niche treatments. Key trends to look out for during the forecast period are developments in gene editing technologies, state-of-the-art diagnostic approaches for early detection, improvements in enzyme replacement therapies, incorporation of precision medicine strategies, and the use of newborn genetic screening programs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

Who are the Major Competitors in the Methylmalonic Acidemia (MMA) Market Outlook?

Major companies operating in the methylmalonic acidemia (MMA) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.

What Is Fueling Growth in the Methylmalonic Acidemia (MMA) Market?

The methylmalonic acidemia (MMA) market is predicted to grow due to an upswing in metabolic disorders and vitamin deficiencies. Metabolic disorders are characterized by the body’s difficulty in breaking down certain nutrients, generating energy, or maintaining chemical balance within cells. Vitamin deficiencies are a result of the body not having sufficient quantities of certain vitamins to function correctly. Unhealthy eating habits, lack of physical exercise, and elevated stress levels are the primary reasons for the rise in metabolic disorders and vitamin deficiencies. Contemporary diets often consist of processed foods, sugars, and unhealthy fats, and lack vital nutrients leading to a deficiency in vitamins and minerals. Metabolic disorders and vitamin deficiencies, notably vitamin B12 deficiency, lead to interference with methylmalonyl-CoA metabolism, causing a build-up of methylmalonic acid and worsening methylmalonic acidemia (MMA). The National Institutes of Health, a US government agency, revealed in November 2024 that the number of vitamin B12 deficiencies climbed from 4.6% to 5.2%, which constitutes an extra 507 cases between the third and fourth quarters of 2023. Therefore, with the rise in metabolic disorders and vitamin deficiencies, the methylmalonic acidemia (MMA) market is set to expand.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22057&type=smp

Which Methylmalonic Acidemia (MMA) Market Segments Are Growing the Fastest?

The methylmalonic acidemia (MMA) market covered in this report is segmented –

1) By Indication: Acidosis, Ketosis, Hyperammonemia, Hypoglycaemia, Hyperglycaemia, Neutropenia, Other Indications

2) By Disorder Type: Homocystinuria, Isolated Methylmalonic Acidurias, Combined methylmalonic Aciduria

3) By Distribution Channel: Hospitals, Pharmacies, Clinics, Other Distribution Channels

Subsegments:

1) By Acidosis: Metabolic Acidosis, Lactic Acidosis

2) By Ketosis: Starvation-Induced Ketosis, Diabetic Ketoacidosis

3) By Hyperammonemia: Acute Hyperammonemia, Chronic Hyperammonemia

4) By Hypoglycemia: Fasting Hypoglycemia, Reactive Hypoglycemi

5) By Hyperglycemia: Transient Hyperglycemia, Persistent Hyperglycemia

6) By Neutropenia: Severe Neutropenia, Cyclic Neutropenia

7) By Other Indications: Failure to Thrive, Developmental Delays, Neurological Symptoms, Renal Dysfunction

Which Industry Trends Are Shaping the Future of the Methylmalonic Acidemia (MMA) Market?

Key players in the methylmalonic acidemia (MMA) market are striving to devise revolutionary solutions such as mRNA-based therapies, aiming to enhance treatment outcomes by addressing the fundamental genetic causes of MMA and boosting enzyme performance to limit the buildup of harmful metabolites in those affected. mRNA-based therapies are medical treatments that employ messenger RNA to guide cells towards producing specific proteins that can effectively prevent or treat conditions including genetic diseases or infections. For example, in June 2024, Moderna, Inc., an American pharmaceutical and biotech firm, obtained approval from the U.S. Food and Drug Administration (FDA) for the inclusion of mRNA-3705 in the START pilot scheme, representing a crucial advancement in the treatment of rare diseases. This investigational therapy for methylmalonic acidemia (MMA) resulting from MUT deficiency aims to replace the deficient enzyme using mRNA technology. The treatment employs Moderna’s unique lipid nanoparticle (LNP) system, which is also in use in the mRNA-3927 program for propionic acidemia. The FDA has bestowed mRNA-3705 with orphan drugs, fast track, and rare pediatric disease designations that will expedite its evolution and clinical progress.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

Which Countries Are Leading the Methylmalonic Acidemia (MMA) Market?

North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22057

This Report Delivers Insight On:

1. How big is the methylmalonic acidemia (mma) market, and how is it changing globally?

2. Who are the major companies in the methylmalonic acidemia (mma) market, and how are they performing?

3. What are the key opportunities and risks in the methylmalonic acidemia (mma) market right now?

4. Which products or customer segments are growing the most in the methylmalonic acidemia (mma) market?

5. What factors are helping or slowing down the growth of the methylmalonic acidemia (mma) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model